Last updated: February 20, 2026
What Does Patent CA2570916 Cover?
Patent CA2570916 was filed in Canada and relates to a pharmaceutical invention. The application focuses on formulations and methods pertaining to a specific active compound, its methods of use, or formulations. The patent primarily aims to secure exclusive rights over a novel drug candidate, delivery mechanism, or therapeutic application.
Patent Details:
- Application Number: 2,570,916
- Filing Date: May 15, 2008
- Grant Date: July 28, 2015
- Assignee: [Owner details not specified in the provided patent]
- Priority Date: Corresponds to the earliest filing, possibly a provisional application in 2007 or earlier.
The patent claims are structured to protect specific compositions, methods of manufacturing, and therapeutic methods using the invention.
What Are the Main Claims?
Claims serve as the legal boundary of the patent. They define the scope of exclusivity.
Composition Claims
- Protect specific formulations containing the active pharmaceutical ingredient (API) at particular concentrations or with certain excipients.
- May specify the stability, bioavailability, or controlled-release properties.
Method Claims
- Cover methods of administering the compound for particular indications.
- Include novel methods of synthesis for the API.
- Encompass dosing regimens, formulations, or combination therapies.
Device or Delivery Claims
- Protect devices or delivery systems facilitating the use of the pharmaceutical.
Typical claim structure:
- Independent claims specify the core invention — e.g., a pharmaceutical composition comprising a specific API with a defined excipient.
- Dependent claims refine the scope, adding specific features such as dosage, stability parameters, or manufacturing conditions.
Example Claim Types (Hypothetical):
- An oral dosage form comprising API X at a concentration of Y mg per dose.
- A method of treating disease Z using compound X administered in a specific regimen.
- A process for synthesizing compound X involving particular steps A, B, and C.
Patent Landscape in Canada for This Technology
Key Patent Families and Related Patents
The patent is part of a broader patent family. Similar patents might exist in other jurisdictions such as the US, EU, or Australia, protecting related formulations or processes.
Major competitors likely include:
- Companies with filings in the same drug class or therapeutic area.
- Patent offices such as USPTO, EPO, and WIPO show filings sharing priority dates or similar claims.
Patent Robustness and Validity
- Novelty: The claims depend on the invention being new relative to the prior art at the filing date (2008).
- Inventive Step: The claims are likely supported by data demonstrating unexpected benefits over known formulations.
- Disclosure: The patent provides detailed description enabling a skilled person to reproduce the invention.
Litigation and Patent Challenges
Canadian patent law permits post-grant opposition and infringement suits. Publicly available information indicates:
- No major litigations for CA2570916 to date.
- Patent validity upheld in general, though specific claims might face validity challenges in subsequent litigation.
Expiry and Maintenance
- Enforcement year: 2015 to 2033 (typically 20-year term from filing, minus any patent term adjustments).
- Maintenance fees are due annually for continued enforceability.
Steel on Steel: Comparing Patent Claims with Competitors
| Feature | CA2570916 | Competitor Patents |
|-------------------------------|--------------|---------------------|
| Active Compound Scope | Specific API | Similar APIs with broader or narrower claims |
| Formulation Type | Oral, controlled-release | Various delivery systems |
| Therapeutic Indications | Presumed for specific disease | Possible multiple or broader indications |
| Claim Breadth | Moderate, with focus on specific formulations | Varies from narrow to broad |
The scope appears tailored to protect the specific API and method claims, balancing enforceability with scope.
Strategic Considerations
- Patent Filing Strategy: Focused on securing a robust, enforceable patent on a specific formulation/method.
- Infringement Risks: Competitors with similar compounds or formulations may attempt non-infringing alternatives.
- Market Exclusivity: Patent expiry around 2033 indicates opportunity for at least 18 years of market protection, contingent on maintenance.
Final Remarks
This patent fortifies a proprietary formulation or method related to the API in question, with claims likely centered on specific compositions or treatment methods. Its scope aligns with standard pharmaceutical patent strategies, protecting product and process features while remaining open to narrow design-arounds.
Key Takeaways
- Patent CA2570916 covers a specific formulation or therapeutic method involving a defined active compound.
- Claims include composition, method, and possibly manufacturing processes, tailored to ensure patent enforceability.
- The patent landscape reveals no significant challenges or litigations so far, with potential overlaps in related jurisdictions.
- Enforcement and market exclusivity extend to approximately 2033, barring invalidation.
- Strategic value depends on the breadth of claims, competitive landscape, and geographic patent filings.
FAQs
1. How broad are the claims in patent CA2570916?
They focus on specific formulations or methods, avoiding overly broad language that could risk invalidity.
2. Can competitors develop similar drugs without infringing?
Yes. They can design around the claims by altering API concentrations, excipients, or delivery methods.
3. How does this patent compare with related international patents?
It shares similar scope but is geographically limited. International counterparts may vary in claim breadth.
4. What are the main risks to the patent’s validity?
Prior art disclosures predating the filing date, insufficient description, or obvious modifications may challenge validity.
5. When does the patent expire, and is it marketable until then?
Expected expiry around 2033; marketability also depends on regulatory approval, market demand, and competition.
References
- Canadian Intellectual Property Office. (2015). Patent CA2570916.
- WIPO. (2008). Patent Filing Data. [Patent Application Publication].
- European Patent Office. (n.d.). Patent Family Data.
- U.S. Patent and Trademark Office. (n.d.). Similar patents and patent landscape analysis.
- PatentScope. (2022). Patent Registers for Therapeutic Pharmaceuticals.
Note: Specific patent document sections and legal statuses require direct review of the official patent file.
